CD274 and neoplasm: NCT04230954 is a single-arm, open label phase II trial to evaluate the efficacy and safety of cabozantinib (XL184; a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, which also inhibits AXL and RET) plus pembrolizumab in 39 patients with recurrent, persistent and/or metastatic CC with PD-L1 tumor positivity.